Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2007011907) ALPHA-SYNUCLEIN ANTIBODIES AND METHODS RELATED THERETO
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2007/011907 International Application No.: PCT/US2006/027772
Publication Date: 25.01.2007 International Filing Date: 19.07.2006
IPC:
C07K 16/18 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
Applicants:
UNIVERSITY OF ROCHESTER [US/US]; 601 Elmwood Avenue, Box OTT Rochester, NY 14642, US (AllExceptUS)
FEDEROFF, Howard, J. [US/US]; US (UsOnly)
MAGUIRE-ZEISS, Kathleen [US/US]; US (UsOnly)
SULLIVAN, Mark [IN/US]; US (UsOnly)
Inventors:
FEDEROFF, Howard, J.; US
MAGUIRE-ZEISS, Kathleen; US
SULLIVAN, Mark; US
Agent:
SPRATT, Gwendolyn, D. ; NEEDLE & ROSENBERG, P.C. SUITE 1000 999 Peachtree Street Atlanta, GA 30309-3915, US
Priority Data:
60/700,56519.07.2005US
Title (EN) ALPHA-SYNUCLEIN ANTIBODIES AND METHODS RELATED THERETO
(FR) ANTICORPS D'ALPHA-SYNUCLEINE ET TECHNIQUES ASSOCIEES
Abstract:
(EN) Disclosed are antibodies specific for alpha-synuclein conformers and methods related thereto. For example, disclosed are methods of diagnosing a neurodegenerative such as Parkinson's disease, monitoring a neurodegenerative disease progression, and monitoring a neurodegenerative disease treatment using the disclosed antibodies. Assays, kits, and solid supports related to alpha-synuclein and antibodies specific for alpha- synuclein are also disclosed.
(FR) La présente invention concerne des anticorps spécifiques de conformères alpha-synucleine et des techniques associées. Par exemple, cette invention concerne des techniques permettant de diagnostiquer une maladie neurodégénérative telle que la maladie de Parkinson, de surveiller une progression de maladie neurodégénérative et de surveiller un traitement de maladie neurodégénérative au moyen des anticorps de l'invention. Cette invention concerne aussi des dosages, des kits et des supports solides associés à alpha-synucleine ainsi que des anticorps spécifiques d' alpha- synucleine..
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP1915177US20080300204CA2657953